


Next-generation cancer diagnostics and treatment monitoring

Cancer is a global health problem, the second leading cause of death worldwide. If we want to address it directly, we need to create tools that can do both: detect cancer at early stages and continuously monitor the efficacy of the treatments applied to patients, for us to personalize cancer therapies through the course of the disease.

<u>Circulating Tumor Cells</u>* (cells derived from primary or metastatic solid tumors that enter the bloodstream) are key to address both needs. The problem is that they are presented in low numbers (1-1k tumor cells in a background of 50B blood cells) and are heterogeneous.

Cytocatch™ has the sensitivity and specificity to isolate a single CTC









At <u>Delee</u>, we created **The CytoCath**, our product insignia, that automatically processes a blood sample* (10 mL) in less than 20 mins and isolates the Circulating Tumor Cells with <u>over 96%</u> capture efficiency. After the isolation, it gives the option to do the analyzes with our designed microscope/slide scanner, which has machine learning algorithms to identify and count the tumoral cells; or do molecular analysis tests by preparing the sample.

Video of how it works: https://www.youtube.com/watch?v=KTSZPOxrvbs

We are backed by Y Combinator and StartX MED and we have developed all our technology in-house and have several patent pending applications, published peer-reviewed articles in premiere scientific journals including Nature that validate our science and the effectiveness of our technology.

Our business model is razors and blades, with revenue obtained from the sale of the technology itself and recurrent revenue from the sale of the needed consumables to perform each test.

We understand our market. We will start sales as a research use only device by Q1 2023. Why? Speed to market because FDA clearance is **NOT** required for this approach. This opportunity alone represents a TAM of \$11.2B that we can engage as early as next year.

We already have 2 pilots scheduled for this January including one at <u>Stanford Medical Center</u> and another with <u>HALO Dx</u> with over 13 sites across the US. We have also secured pre-orders worth a potential value of \$2.5M from client research centers.

Once our technology obtains FDA clearance in 2025, it will be commercialized as a general diagnostic medical device for use in hospitals and laboratories, which represents a massive TAM of \$543B.

To sum this up - we are delivering a superior product to a giant market which is NOT winner take all.

Delee Corp. - www.delee.co, Liza Velarde (CEO) - liza@delee.bio